Literature DB >> 28760671

Application of phospho-CyTOF to characterize immune activation in patients with sickle cell disease in an ex vivo model of thrombosis.

Jeffrey Glassberg1, Adeeb H Rahman2, Mohammad Zafar3, Caroline Cromwell4, Alexa Punzalan5, Juan Jose Badimon6, Louis Aledort7.   

Abstract

Sickle cell disease (SCD) is a genetic disease caused by mutations in the beta globin gene, and inflammation plays a key role in driving many aspects of disease pathology. Early immune activation is believed to be associated with hemodynamic stresses and thrombus formation as cells traffic through blood vessels. We applied an extracorporeal perfusion system to model these effects ex vivo, and combined this with a phospho-CyTOF workflow to comprehensively evaluate single-cell signatures of early activation across all major circulating immune subsets. These approaches showed immune activation following passage through the perfusion chamber, most notably in monocytes, which exhibited platelet aggregation and significantly elevated expression of multiple phospho-proteins. Overall, these studies outline a robust and broadly applicable workflow to leverage phospho-CyTOF to characterize immune activation in response to ex vivo or in vivo perturbations and may facilitate identification of novel therapeutic targets in SCD and other inflammatory diseases.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Immunology; Mass cytometry; Phospho-protein; Sickle cell disease; Signaling; Thrombosis

Mesh:

Substances:

Year:  2017        PMID: 28760671      PMCID: PMC7487207          DOI: 10.1016/j.jim.2017.07.014

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  25 in total

1.  Platelet activation and endothelial cell dysfunction in sickle cell disease is unrelated to reduced antioxidant capacity.

Authors:  Andrew D Blann; Sukhjinder Marwah; Graham Serjeant; David Bareford; Josh Wright
Journal:  Blood Coagul Fibrinolysis       Date:  2003-04       Impact factor: 1.276

2.  Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum.

Authors:  Sean C Bendall; Erin F Simonds; Peng Qiu; El-ad D Amir; Peter O Krutzik; Rachel Finck; Robert V Bruggner; Rachel Melamed; Angelica Trejo; Olga I Ornatsky; Robert S Balderas; Sylvia K Plevritis; Karen Sachs; Dana Pe'er; Scott D Tanner; Garry P Nolan
Journal:  Science       Date:  2011-05-06       Impact factor: 47.728

3.  Tapered oral dexamethasone for the acute chest syndrome of sickle cell disease.

Authors:  Charles T Quinn; Marie J Stuart; Karen Kesler; Kenneth I Ataga; Winfred C Wang; Lori Styles; Kim Smith-Whitley; Ted Wun; Ashok Raj; Lewis L Hsu; Suba Krishnan; Frans A Kuypers; Yamaja Setty; Seungshin Rhee; Nigel S Key; George R Buchanan
Journal:  Br J Haematol       Date:  2011-08-16       Impact factor: 6.998

4.  Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis.

Authors:  A J Duits; R C Pieters; A W Saleh; E van Rosmalen; H Katerberg; K Berend; R A Rojer
Journal:  Clin Immunol Immunopathol       Date:  1996-10

5.  Steady-state sVCAM-1 serum levels in adults with sickle cell disease.

Authors:  J B Schnog; R A Rojer; M R Mac Gillavry; H Ten Cate; D P M Brandjes; A J Duits
Journal:  Ann Hematol       Date:  2003-02-11       Impact factor: 3.673

6.  Multiplexed mass cytometry profiling of cellular states perturbed by small-molecule regulators.

Authors:  Bernd Bodenmiller; Eli R Zunder; Rachel Finck; Tiffany J Chen; Erica S Savig; Robert V Bruggner; Erin F Simonds; Sean C Bendall; Karen Sachs; Peter O Krutzik; Garry P Nolan
Journal:  Nat Biotechnol       Date:  2012-09       Impact factor: 54.908

7.  Heparin reduces nonspecific eosinophil staining artifacts in mass cytometry experiments.

Authors:  Adeeb H Rahman; Leticia Tordesillas; M Cecilia Berin
Journal:  Cytometry A       Date:  2016-04-06       Impact factor: 4.355

Review 8.  Hemostatic abnormalities in sickle cell disease.

Authors:  Ming Y Lim; Kenneth I Ataga; Nigel S Key
Journal:  Curr Opin Hematol       Date:  2013-09       Impact factor: 3.284

9.  Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber.

Authors:  Mohammad Urooj Zafar; David A Vorchheimer; Juan Gaztanaga; Mauricio Velez; Daniel Yadegar; Pedro R Moreno; Satoshi Kunitada; Juan Pagan; Valentin Fuster; Juan J Badimon
Journal:  Thromb Haemost       Date:  2007-10       Impact factor: 5.249

10.  Inflammation in Sickle Cell Disease: Differential and Down-Expressed Plasma Levels of Annexin A1 Protein.

Authors:  Lidiane S Torres; Jéssika V Okumura; Danilo G H Silva; Kallyne K O Mimura; Édis Belini-Júnior; Renan G Oliveira; Clarisse L C Lobo; Sonia M Oliani; Claudia R Bonini-Domingos
Journal:  PLoS One       Date:  2016-11-01       Impact factor: 3.240

View more
  4 in total

1.  Unraveling function and diversity of bacterial lectins in the human microbiome.

Authors:  Louis J Cohen; Sean F Brady; Sun M Han; Pearson Lau; Daniela Guisado; Yupu Liang; Toshiki G Nakashige; Thamina Ali; David Chiang; Adeeb Rahman
Journal:  Nat Commun       Date:  2022-06-03       Impact factor: 17.694

Review 2.  Platelet Proteomes, Pathways, and Phenotypes as Informants of Vascular Wellness and Disease.

Authors:  Joseph E Aslan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-01-14       Impact factor: 8.311

3.  A streamlined whole blood CyTOF workflow defines a circulating immune cell signature of COVID-19.

Authors:  Daniel Geanon; Brian Lee; Edgar Gonzalez-Kozlova; Geoffrey Kelly; Diana Handler; Bhaskar Upadhyaya; John Leech; Ronaldo M De Real; Manon Herbinet; Assaf Magen; Diane Del Valle; Alexander Charney; Seunghee Kim-Schulze; Sacha Gnjatic; Miriam Merad; Adeeb H Rahman
Journal:  Cytometry A       Date:  2021-02-16       Impact factor: 4.714

Review 4.  Immune cell profiling in atherosclerosis: role in research and precision medicine.

Authors:  Dawn M Fernandez; Chiara Giannarelli
Journal:  Nat Rev Cardiol       Date:  2021-07-15       Impact factor: 32.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.